VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study

Validate accuracy of the Breast cancer therapeutic response predictive algorithm for predicting pathological complete response (pCR) in the early TNBC population treated with neoadjuvant chemotherapy.,Identify women with chemotherapy sensitive and chemotherapy resistant breast cancers.

Background: Despite improvements in the treatment of Triple Negative Breast Cancer (TNBC),
 the cancer returns in half of the women and shockingly 40% are dead within 5 years of their
 initial cancer diagnosis. There is an urgent need to identify reliable biomarkers of response
 for chemotherapy and immunotherapy.
 
 Study Aims: To update Concr's existing predictive algorithms specifically for use in women
 newly diagnosed with TNBC.
 
 The plan is develop technology which will predict which drug the cancer will respond best to,
 treatment A vs. treatment B AND how the individual's prognosis could change if treatment A is
 chosen overtreatment B.
 
 Study Design: The VISION study is a clinical study looking back in time (retrospective
 study), specifically focusing on women who were previously diagnosed with early Triple
 Negative breast cancer and received chemotherapy followed by curative breast surgery. The
 plan is to collect historical clinical data and previously collected cancer biopsy samples
 from up to 200 women in order to update Concr's existing treatment prediction algorithms.
 Hence there are no extra research biopsies needed in order to participate in the Study.
 
 Study Sites: UK and Australia
 
 Study Funding: This study is funded by the a Techbio company called Concr with support from
 Innovate UK (UK Government funding).